항체 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 원료별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Antibodies Contract Manufacturing Market Summary

The global antibodies contract manufacturing market size was valued at USD 19.7 billion in 2025 and is projected to grow from USD 21.5 billion in 2026 to USD 41.0 billion by 2033, at a CAGR of 9.7% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 34.1% in 2025. The growing focus of biopharmaceutical and biotechnology companies on manufacturing antibody therapeutics is a significant factor driving market growth.

Market Dynamics

The antibodies contract manufacturing market is driven by surging demand for monoclonal antibodies across oncology, autoimmune disorders, and infectious diseases, alongside a robust pipeline of bispecific and next-generation antibody therapeutics. The biopharmaceutical companies outsource production in large numbers to mitigate capital expenditure on bioreactor infrastructure while leveraging CMO expertise in upstream and downstream processing, cell line development, and analytical characterization. In addition, rising approvals of biologics and expanding indications for existing antibody drugs are reinforcing sustained demand for manufacturing. The rising advancements in single-use bioprocessing technologies are enabling faster, more flexible production scale-up for CMOs serving both clinical and commercial-stage clients. However, capacity constraints during peak demand periods, high switching costs, and stringent regulatory compliance requirements pose challenges for new market entrants. Moreover, geopolitical supply chain disruptions and rising raw material costs are prompting manufacturers to diversify production footprints across multiple regions, including emerging Asia Pacific markets.

Global Antibodies Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibodies contract manufacturing market report based on product, source, end use, and region:

• Product Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Monoclonal Antibodies
• Polyclonal Antibodies
• Others
• Source Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Mammalian
• Microbial
• End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Biopharmaceutical Companies
• Research Laboratories
• Others
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Source
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Antibodies Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Monoclonal Antibodies Therapeutics
    • 3.2.1.2. Growing Focus of Biopharmaceutical and Biotechnology Companies
    • 3.2.1.3. Increasing Outsourcing by Biopharmaceutical Companies to Specialized CMOs
    • 3.2.1.4. Expansion of Biologics Clinical Pipelines and Regulatory Approvals
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Manufacturing Complexity and Production Costs
    • 3.2.2.2. Stringent Regulatory Compliance and Lengthy Validation Processes
• 3.3. Pricing Model Analysis
• 3.4. Tariff Impact Analysis
• 3.5. Value Chain Analysis
  • 3.5.1. Supply Trends
  • 3.5.2. Demand Trends
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Antibodies Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Antibodies Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. Antibodies Contract Manufacturing Market, By Product: Movement Analysis
• 4.3. Antibodies Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million/Billion)
• 4.4. Monoclonal Antibodies
  • 4.4.1. Monoclonal Antibodies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.5. Polyclonal Antibodies
  • 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.6. Others
  • 4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Antibodies Contract Manufacturing Market: Source Estimates & Trend Analysis

• 5.1. Antibodies Contract Manufacturing Market, By Source: Segment Dashboard
• 5.2. Antibodies Contract Manufacturing Market, By Source: Movement Analysis
• 5.3. Antibodies Contract Manufacturing Market Estimates & Forecasts, By Source, 2021 - 2033 (USD Million/Billion)
• 5.4. Mammalian
  • 5.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.5. Microbial
  • 5.5.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Antibodies Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Antibodies Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Antibodies Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Antibodies Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million/Billion)
• 6.4. Biopharmaceutical Companies
  • 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.5. Research Laboratories
  • 6.5.1. Research Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Antibodies Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.4. Saudi Arabia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.6. Qatar
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 7.7.7. Oman
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Samsung Biologics
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. WuXi Biologics
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Charles River Laboratories
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. FUJIFILM Holdings Corporation
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Boehringer Ingelheim Biopharmaceuticals GmbH
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. AGC Biologics
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Cytovance Biologics, Inc.
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. EMERGENT
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Thermo Fisher Scientific
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Labcorp Drug Development
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Catalent, Inc.
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives